Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2021 1
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, Gagliardini R, Notari S, Mazzotta V, Mariotti D, Cicalini S, Girardi E, Vaia F, Maggi F, Antinori A; HIV-VAC Study group. Vergori A, et al. Among authors: fusto m. Int J Infect Dis. 2023 Sep;134:195-199. doi: 10.1016/j.ijid.2023.06.010. Epub 2023 Jun 19. Int J Infect Dis. 2023. PMID: 37343783 Free PMC article.
Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH.
Gagliardini R, Vergori A, Lorenzini P, Cicalini S, Pinnetti C, Mazzotta V, Mondi A, Mastrorosa I, Camici M, Lanini S, Fusto M, Paulicelli J, Plazzi MM, Marchioni L, Agrati C, Garbuglia AR, Piselli P, Nicastri E, Taglietti F, Palmieri F, D'Offizi G, Girardi E, Vaia F, Antinori A. Gagliardini R, et al. Among authors: fusto m. J Clin Med. 2022 Mar 11;11(6):1546. doi: 10.3390/jcm11061546. J Clin Med. 2022. PMID: 35329872 Free PMC article.
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. Among authors: fusto m. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH.
Vergori A, Cozzi-Lepri A, Matusali G, Colavita F, Cicalini S, Gallì P, Garbuglia AR, Fusto M, Puro V, Maggi F, Girardi E, Vaia F, Antinori A; HIV-VAC Study Group. Vergori A, et al. Among authors: fusto m. Viruses. 2022 Aug 3;14(8):1710. doi: 10.3390/v14081710. Viruses. 2022. PMID: 36016332 Free PMC article.
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S, Iannazzo R, Mazzotta V, Colavita F, Mastrorosa I, Cimini E, Mariotti D, De Pascale L, Marani A, Gallì P, Garbuglia A, Castilletti C, Puro V, Agrati C, Girardi E, Vaia F, Antinori A; HIV-VAC study group. Vergori A, et al. Nat Commun. 2022 Aug 22;13(1):4922. doi: 10.1038/s41467-022-32263-7. Nat Commun. 2022. PMID: 35995780 Free PMC article.
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.
Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, Mazzotta V, Colavita F, Fusto M, Cimini E, Notari S, D'Aquila V, Lanini S, Lapa D, Gagliardini R, Mariotti D, Giannico G, Girardi E, Vaia F, Agrati C, Maggi F, Antinori A. Vergori A, et al. Among authors: fusto m. Vaccines (Basel). 2023 Nov 22;11(12):1739. doi: 10.3390/vaccines11121739. Vaccines (Basel). 2023. PMID: 38140145 Free PMC article.
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, Cozzi Lepri A, Gallì P, Pinnetti C, Gagliardini R, Mazzotta V, Mastrorosa I, Grisetti S, Colavita F, Cimini E, Grilli E, Bellagamba R, Lapa D, Sacchi A, Marani A, Cerini C, Candela C, Fusto M, Puro V, Castilletti C, Agrati C, Girardi E, Vaia F; HIV-VAC Study Group. Antinori A, et al. Among authors: fusto m. Clin Infect Dis. 2022 Aug 24;75(1):e552-e563. doi: 10.1093/cid/ciac238. Clin Infect Dis. 2022. PMID: 35366316 Free PMC article.
Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Mastrorosa I, Pinnetti C, Brita AC, Mondi A, Lorenzini P, Del Duca G, Vergori A, Mazzotta V, Gagliardini R, Camici M, De Zottis F, Fusto M, Plazzi MM, Grilli E, Bellagamba R, Cicalini S, Antinori A. Mastrorosa I, et al. Among authors: fusto m. Clin Infect Dis. 2023 Feb 8;76(3):e629-e637. doi: 10.1093/cid/ciac658. Clin Infect Dis. 2023. PMID: 35982541 Free PMC article.
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, Antinori A; Mpox Vaccine Lazio Study Group. Mazzotta V, et al. EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38292040 Free PMC article.
Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation.
Ciccosanti F, Antonioli M, Sacchi A, Notari S, Farina A, Beccacece A, Fusto M, Vergori A, D'Offizi G, Taglietti F, Antinori A, Nicastri E, Marchioni L, Palmieri F, Ippolito G, Piacentini M, Agrati C, Fimia GM. Ciccosanti F, et al. Among authors: fusto m. Clin Proteomics. 2022 Nov 8;19(1):38. doi: 10.1186/s12014-022-09377-7. Clin Proteomics. 2022. PMID: 36348270 Free PMC article.
13 results